Search Results - "Kosty, M"

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey by Cufer, T., Kosty, M., Osterlund, P., Jezdic, S., Pyle, D., Awada, A., Close, J., El-Saghir, N., Lordick, F., Rutkowski, P., Tfayli, A., Wildiers, H.

“…With the implementation of multidisciplinary treatment and development of multiple novel anticancer drugs in parallel with expanding knowledge of supportive…”
Get full text

Association Between Geographic Access and Receipt of Radiation Therapy by Lin, C.C, Bruinooge, S, Kirkwood, K, Hershman, D.L, Jemal, A, Yu, J.B, Guadagnolo, B.A, Hopkins, S, Goldstein, M, Bajorin, D, Giordano, S, Kosty, M, Arnone, A, Hanley, A, Stevens, S, Olsen, C.C

Get full text

Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study by Wozniak, A.J, Kosty, M.P, Jahanzeb, M, Brahmer, J.R, Spigel, D.R, Leon, L, Fish, S, Flick, E.D, Hazard, S.J, Lynch, T.J

“…Abstract Aims Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on…”
Get full text

Merkel cell carcinoma : Review of 22 cases with surgical, pathologic, and therapeutic considerations by GOLLARD, R, WEBER, R, KOSTY, M. P, GREENWAY, H. T, MASSULLO, V, HUMBERSON, C

“…Merkel cell carcinoma is a primary small blue cell tumor of the skin with a proclivity to metastasize. Surgery and radiation therapy have defined roles in the…”
Get full text

Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies by Meisenberg, B R, Miller, W E, McMillan, R, Callaghan, M, Sloan, C, Brehm, T, Kosty, M P, Kroener, J, Longmire, R, Saven, A, Piro, L D

“…A prospective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell rescue (ASCR) in the outpatient setting. One hundred…”
Get more information

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma by Saven, A, Lee, T, Kosty, M, Piro, L

“…Since cladribine (2-chlorodeoxyadenosine [2-CdA]) and mitoxantrone both exhibit major activity against indolent lymphoid malignancies and have different…”
Get more information

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia by Saven, A, Lemon, R H, Kosty, M, Beutler, E, Piro, L D

“…2-chlorodeoxyadenosine (2-CdA; cladribine) is a purine analog with activity in patients with chronic lymphocytic leukemia (CLL) who fail to respond to…”
Get more information

Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B by Kosty, M P, Fleishman, S B, Herndon, 2nd, J E, Coughlin, K, Kornblith, A B, Scalzo, A, Morris, J C, Mortimer, J, Green, M R

“…To assess the chemotherapy regimen of cisplatin, vinblastine, and hydrazine sulfate administered to patients with non-small-cell lung cancer (NSCLC) in a…”
Get more information

Outcomes Among African-American/Non-African-American Patients With Advanced Non-Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B by Blackstock, A. William, Herndon, James E., Paskett, Electra D., Perry, Michael C., Graziano, Stephen L., Muscato, Joseph J., Kosty, Michael P., Akerley, Wallace L., Holland, Jimmie, Fleishman, Stewart, Green, Mark R.

“…Background: Among patients diagnosed with advanced non-small-cell lung carcinoma (NSCLC), African-Americans have lower survival rates than…”
Get full text

9006 Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS) by Jahanzeb, M, Fischbach, N, Kosty, M, Kumar, P, Spigel, D, Wozniak, A, Teng, S.L, Wang, L, Sing, A, Lynch, T

Get full text

An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant by FRAKES, L. A, BREHM, T. L, KOSTY, M. P, MILLER, W. E, MCMILLAN, R. L, MASON, J, MEISENBERG, B. R

“…The purpose of the study was to assess the toxicity and efficacy of an oral, combination antiemetic regimen including granisetron (Kytril; SmithKline Beecham…”
Get full text

1826P Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: A global survey by Cufer, T., Kosty, M., Osterlund, P.J., Jezdic, S., Pyle, D., Awada, A., Close, J., El-Saghir, N., Lordick, F., Rutkowski, P., Tfayli, A., Wildiers, H.

Get full text

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy by Saven, A, Cheung, W K, Smith, I, Moyer, M, Johannsen, T, Rose, E, Gollard, R, Kosty, M, Miller, W E, Piro, L D

“…This study was designed to evaluate the absolute bioavailability (F value) of 2-chlorodeoxyadenosine (cladribine; 2-CdA) after multiple oral administrations,…”
Get more information

Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD by Kornblith, A B, Anderson, J, Cella, D F, Tross, S, Zuckerman, E, Cherin, E, Henderson, E S, Canellos, G P, Kosty, M P, Cooper, M R

“…Survivors of advanced Hodgkin disease, who were assigned randomly to treatment by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP);…”
Get more information

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors by Kaul, S, Igwemezie, L N, Stewart, D J, Fields, S Z, Kosty, M, Levithan, N, Bukowski, R, Gandara, D, Goss, G, O'Dwyer, P

“…To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (i.v.) administration of etoposide phosphate (Etopophos; Bristol-Myers…”
Get more information

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016 by Dittrich, C., Kosty, M., Jezdic, S., Pyle, D., Berardi, R., Bergh, J., Lotz, J.-P., Österlund, P., Pavlidis, N., Purkalne, G., Carraway, Hetty, Lee Close, Julia, Gilbert, Jill, Bokemeyer, Carsten, Cervantes, Andrés, Ohe, Yuichiro, Pless, Miklos, McGregor, Keith, Fumassoli, Katharine, Candiani, Roberta, Bricalli, Gracemarie, Kenny, Tanya, Latino, Nicola, Cogo, Marina, Pavinato, Vanessa, Marchesi, Vanessa, Awada, Ahmad, Banerjee, Susana, Bhatia, Smita, Bogaerts, Jan, Buckner, Jan, Cardoso, Fatima, Casali, Paolo, Chu, Edward, Coiffier, Bertrand, Connolly, Roisin, Coupland, Sarah, De Petris, Luigi, De Santis, Maria, de Vries, Elisabeth G.E., Dizon, Don S., Duff, Jennifer, Duska, Linda R., Eniu, Alexandru, Ernstoff, Marc, Felip, Enriqueta, Fey, Martin F., Glaudemans, Andor W.J.M., Gopalan, Priya K., Grothey, Axel, Hahn, Stephen M., Hanna, Diana, Herold, Christian, Herrstedt, Jørn, Homicsko, Krisztian, Jones, Dennie V., Jost, Lorenz, Keilholz, Ulrich, Khan, Saad, Kiss, Alexander, Köhne, Claus-Henning, Kunstfeld, Rainer, Lichtman, Stuart, Licitra, Lisa, Lion, Thomas, Litière, Saskia, Loehrer, Patrick J., Jennifer Markham, Merry, Markman, Ben, Mayerhoefer, Marius, Meran, Johannes G., Michielin, Olivier, Charlotte Moser, Elizabeth, Mountzios, Giannis, Moynihan, Timothy, Palumbo, Antonio, Alessandro Peccatori, Fedro, Pfeilstöcker, Michael, Raut, Chandrajit, Remick, Scot C., Rutkowski, Piotr, Salgado, Roberto, Schernhammer, Eva, Schlumberger, Martin, Schmoll, Hans-Joachim, Schnipper, Lowell, Sessa, Cristiana, Shapiro, Charles L., Steele, Julie, Sternberg, Cora N., Stiefel, Friedrich, Sullivan, Richard, Tabernero, Josep, Travado, Luzia, Verheij, Marcel, Voest, Emile, Von Roenn, Jamie, Weber, Jeffrey S., Wildiers, Hans, Yarden, Yosef

Get full text

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK by von Pawel, J., Syrigos, K., Mazieres, J., Cortinovis, D., Dziadziuszko, R., Gandara, D.R., Conkling, P., Goldschmidt, J., Thomas, C.A., Bordoni, R., Kosty, M., Braiteh, F.S., Hu, S., Ballinger, M., Patel, H., Gandhi, M., Fehrenbacher, L.

Get full text

Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK by Cortinovis, D., von Pawel, J., Syrigos, K., Mazieres, J., Dziadziuszko, R., Fehrenbacher, L., Conkling, P., Goldschmidt, J., Thomas, C.A., Bordoni, R., Kosty, M., Braiteh, F.S., He, P., Ballinger, M., Gandhi, M., Patel, H., Gandara, D.R.

Get full text

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies by Saven, A, Kawasaki, H, Carrera, C J, Waltz, T, Copeland, B, Zyroff, J, Kosty, M, Carson, D A, Beutler, E, Piro, L D

“…We performed a dose-escalation study of 2-chlorodeoxyadenosine (2-CdA) in solid tumors to determine the maximum-tolerated dose (MTD) and define its toxicity…”
Get more information

Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma by Elias, D J, Kline, L E, Robbins, B A, Johnson, Jr, H C, Pekny, K, Benz, M, Robb, J A, Walker, L E, Kosty, M, Dillman, R O

“…The antigen reactive with murine monoclonal antibody (MAb) KS1/4 is expressed on epithelial malignancies and some normal epithelial tissues. Studies were…”
Get more information